Interleukin-12 targeted to oncofoetal fibronectin
Details for Australian Patent Application No. 2005203962 (hide)
International Classifications
Event Publications
27 July 2006 PCT application entered the National Phase
PCT publication WO2005/066348 Priority application(s): WO2005/066348
7 October 2010 Application Accepted
Published as AU-B-2005203962
12 May 2011 Assignment before Grant
Antisoma PLC; EMD Lexigen Research Center Corp. The application has been assigned to Merck Patent GmbH; Antisoma Research Limited
21 July 2011 Standard Patent Sealed
21 June 2012 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 23 May 2012 . Address for service in Australia - Griffith Hack GPO Box 1285 Melbourne VIC 3001
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005203972-Cysteine protease inhibitors
2005203946-Means for fixing or lashing a product, and information means
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser